Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia

Leukemia and Lymphoma

Volumn 53, Issue 8, 2012, Pages 1543-1551

  Wang, Eunice S ^a   Yee, Karen ^b   Koh, Liang Piu ^c   Hogge, Donna ^d   Enschede, Sari ^e   Carlson, Dawn M ^e   Dudley, Matthew ^e   Glaser, Keith ^e   McKeegan, Evelyn ^e   Albert, Daniel H ^e   Li, Xiaohui ^e   Pradhan, Rajendra ^e   Stock, Wendy ^f  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

^e ABBOTT LABORATORIES   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

acute myeloid leukemia; cytarabine; FLT3 inhibitor; Linifanib

Indexed keywords

CD135 ANTIGEN; CYTARABINE; LINIFANIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BEDTIME DOSAGE; BLAST CELL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE DUPLICATION; GENE MUTATION; HEADACHE; HUMAN; HUMAN TISSUE; HYPERTENSION; INFECTION; INTERNAL TANDEM DUPLICATION; LEUKEMIA RELAPSE; LEUKOCYTE; MALE; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PAIN; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEINURIA; REFRACTORY PERIOD; SEPSIS; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VOMITING; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; INDAZOLES; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PHENYLUREA COMPOUNDS; RECURRENCE; TREATMENT OUTCOME;

EID: 84864264337     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.660631     Document Type: Article

References (30)

1. D ohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-474.
2. N CCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Acute Myeloid Leukemia, version 2.2011. Available from: www.nccn.org
3. C amera A, Rinaldi CR, Palmieri S, et al. Sequential continuous infusion of fl udarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients. Ann Hematol 2009;88:151-158.
4. S tone RM, O'Donnell MR, Sekeres MA. Acute myeloid leukemia.Hematology Am Soc Hematol Educ Program 2004:98-117.
5. Shih LY, Huang CF, Wu JH, et al. Heterogeneous patterns of FLT3 Asp(835) mutations in relapsed de novo acute myeloid leukemia: A comparative analysis of 120 paired diagnostic and relapse bone marrowsamples. Clin Cancer Res 2004;10:1326-1332.
6. H u S, Niu H, Minkin P, et al. Comparison of antitumor eff ects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. Mol Cancer Ther 2008;7:1110-1120.
7. Zhou J, Goh B-C, Albert D, et al. ABT-869, a promising multitargetedtyrosine kinase inhibitor: from bench to bedside. J Hematol Oncol 2009;2:33.
8. Kim KT, Baird K, Ahn JY, et al. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood2005;105:1759-1767.
9. S awyers CL. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell 2002;1:413-415.
10. Shih LY, Huang CF, Wu JH, et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis ofbone marrow samples from 108 adult patients at diagnosis and relapse. Blood 2002;100:2387-2392.
11. M etzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009;113:6567-6571.
12. K napper S, Burnett AK, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as fi rst-line treatment for older patients with acute myeloid leukemia not considered fi t for intensivechemotherapy. Blood 2006;108:3262-3270.
13. Wiernik PH. FLT3 inhibitors for the treatment of acute myeloid leukemia. Clin Adv Hematol Oncol 2010;8:429-444.
14. S hankar DB, Li J, Tapang P, et al. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood 2007;109: 3400-3408.
15. Albert DH, Tapang P, Magoc TJ, et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006;5:995-1006.
16. Zhou J, Pan M, Xie Z, et al. Synergistic antileukemic eff ects between ABT-869 and chemotherapy involve downregulation of cellcycle-regulated genes and c-Mos-mediated MAPK pathway. Leukemia 2008;22:138-146.
17. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006. Available from: http://ctep. cancer.gov
18. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-4649.
19. Sato T, Yang X, Knapper S, et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 2011;117:3286-3293.
20. Roukos DH, Tzakos A, Zografos G. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.Expert Rev Anticancer Ther 2009;9:1413-1416.
21. Wong C-I, Koh T-S, Soo R, et al. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 2009;27:4718-4726.
22. Kumar R, Crouthamel M-C, Rominger D, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br JCancer 2009;101:1717-1723.
23. Ravandi F, Cortes JE, Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010;28:1856-1862.
24. Crump M, Hedley D, Kamel-Reid S, et al. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leuk Lymphoma 2010;51:252-260.
25. Borthakur G, Kantarjian H, Ravandi F, et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.Haematologica 2011;96:62-68.
26. Fischer T, Stone RM, DeAngelo DJ, et al. Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome wiTheither wild-typeor mutated FLT3. J Clin Oncol 2010;28:4339-4345.
27. L evis M, Ravandi F, Wang ES, et al. Results from a randomizedtrial of salvage chemotherapy followed by lestaurtinib for patients withFLT3 mutant AML in fi rst relapse. Blood 2011;117:3294-3301.
28. P ratz KW, Cho E, Levis MJ, et al. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.Leukemia 2010;24:1437-1444.
29. P ratz KW, Cortes J, Roboz GJ, et al. A pharmacodynamic studyof the FLT3 inhibitor KW-2449 yields insight into the basis for clinicalresponse. Blood 2009;113:3938-3946.
30. Swerdlow SH, Campo E, Harris NL, et al., editors. WHOclassification of tumours of haematopoietic and lymphoid tissues. 4thed. Lyon, France: IARC; 2008.